Login to Your Account



Milestones Could Reach $1.3B

AVEO Records 'Tivo' Deal with Astellas: $125M Up Front

By Jennifer Boggs


Thursday, February 17, 2011
AVEO Pharmaceuticals Inc. pulled in a whopping $125 million up front in a deal with Astellas Pharma Inc. for Phase III-stage tyrosine kinase inhibitor tivozanib, proving that strong data and promising market potential can prevail even in a buyer's market.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription